Friday 6 November 2026 Export KRYS’s income statement to Excel — free account

Krystal Biotech, Inc.

Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.

Revenue: +30.2%
EPS: −22.3%
Free cash flow: +137.8%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

301.33 1.08 +0.36%

Follow KRYS

Alert me

Market cap: $8.9B
P/E: 39.2×
Fwd P/E: 45.7×
Dividend yield: —
F-score: 7/9
Altman Z: 39.03
Beneish M: −2.27
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Valuation Filings

Krystal Biotech, Inc. (KRYS) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Krystal Biotech, Inc. (KRYS) trades at a P/S ratio of 18.9×. Over the past ten years it has ranged from 0.0× (June 2024) to 36.8× (July 2024); the current reading is higher than 86% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/KRYS/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Krystal Biotech, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/KRYS/metrics/ps-ratio">Krystal Biotech, Inc. (KRYS) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	18.3×	18.94%
FY2024	15.4×	—
FY2023	0.0×	—

Period	P/S ratio	Change
Sep 2026	21.0×	(15.92%)
Jun 2026	24.9×	37.43%
Mar 2026	18.1×	(1.13%)
Dec 2025	18.3×	33.89%
9 more quarters	Free account

Against its own ten years

Low 0.0× High 36.8×

Ten-year median 0.0×

Current reading's percentile 86

Company	P/S ratio
CAI Caris Life Sciences,�Inc. compare	7.1×
MDGL Madrigal Pharmaceuticals, Inc. compare	8.2×
TGTX TG Therapeutics, Inc. compare	10.3×
TWST Twist Bioscience Corporation compare	17.6×
KRYS Krystal Biotech, Inc.	18.9×
PTGX Protagonist Therapeutics, Inc. compare	31.7×
IBRX ImmunityBio, Inc. compare	51.0×
CYTK Cytokinetics, Incorporated compare	64.4×
SYRE Spyre Therapeutics, Inc. compare	8,160×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Krystal Biotech, Inc. (KRYS) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on KRYS

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on KRYS

Stockrow Weekly